Licensing and Collaborative Agreements (Details Narrative) - USD ($)							1 Months Ended				3 Months Ended								12 Months Ended
	Mar. 25, 2016	Dec. 11, 2015	Nov. 23, 2015	Nov. 11, 2015	Sep. 02, 2015	Oct. 10, 2012	Mar. 31, 2016	Nov. 30, 2015	Jan. 31, 2015	Jul. 31, 2010	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2009	Mar. 31, 2008
Research and development expenses											$ 1,097,000	$ 806,000	$ 1,656,000	$ 373,000	$ 956,000	$ 445,000	$ 558,000	$ 474,000	$ 3,931,600	$ 2,432,700
Aggregate face amount															$ 1,302,600					1,302,600
Warrant [Member]
Research and development expenses				$ 135,100	$ 2,840,700		$ 127,100
Number of shares issued	230,000	37,500	7,500	1,123,533	650,000			15,750	381,000
Cato Research Ltd. [Member] | 7.5% Unsecured Promissory Note [Member]
Aggregate face amount						$ 1,009,000
Cato Research Ltd. [Member] | 7.5% Unsecured Promissory Note [Member] | Warrant [Member]
Number of shares issued						50,450
VistaGen California's [Member] | Cato Research Ltd. [Member]
Research and development expenses																			$ 52,600	$ 38,100
U.S.National Institutes Of Health With Preclinical Development Agreement [Member] | VistaGen California's [Member] | AV-101 [Member]
Grant receivable																					$ 4,200,000	$ 4,200,000
Subsequently increased grant receivable										$ 4,600,000